Expression and Extinction of Morphine-Related Aversive Memories in Mice: Underlying Neural Substrates and Impact of Morphine Encapsulation in Liposomes
<p id="p1">The conditioned-place aversion (CPA) paradigm is a widely used animal model for determining the dysphoric and aversive properties of withdrawal, as well as to study the neural substrates underlying the aversive memory associated with drug withdrawal. Therefore, one of the aims of the pres...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2025
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/89826 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | <p id="p1">The conditioned-place aversion (CPA) paradigm is a widely used animal model for determining the dysphoric and aversive properties of withdrawal, as well as to study the neural substrates underlying the aversive memory associated with drug withdrawal. Therefore, one of the aims of the present chapter was to investigate possible strain differences in morphine-withdrawn mice after CPA training. Different studies have shown that corticotrophin-releasing factor (CRF) is critically involved in aversion-driven associative learning. So, we also measured the effects of CP-154,526, a selective CRF1 receptor (CRF1R) antagonist, on CPA activation and extinction and on brain-derived neurotrophic factor (BDNF) expression in dentate gyrus (DG) and basolateral amygdala (BLA), two limbic areas that play a critical role in emotional learning and memory. In the last section of the chapter, we show our main results concerning the effects of encapsulating morphine in liposomes on CPA expression and extinction. Our results indicate a crucial role for CRF, through CRF1R, in molecular changes involved in aversive memory expression and extinction demonstrating that CRF1R antagonists might be a potential therapeutic target in drug addiction. Finally, morphine encapsulation in liposomes could mitigate the progress of addiction and constitute a good option for the therapeutic use of this drug.</p> |
|---|---|
| ISBN: | 978-0-85014-507-6 |
| DOI: | 10.5772/intechopen.115650 |